Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Natick, Massachusetts, United States, 01760
- US Army Research Institute of Environmental Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men aged 18 - 39 years
- Born at altitudes less than 2,100 m
- Physically active (exercise minimum 2 days per week)
- Have supervisor approval (permanent party military and civilians)
- Willing to refrain from alcohol, smokeless nicotine products and dietary supplement use during study periods
- Fully vaccinated against COVID-19
Exclusion Criteria:
- Born at altitudes greater than 2,100 m
- Musculoskeletal injuries that compromise exercise capability
- Metabolic or cardiovascular abnormalities, or gastrointestinal disorders
- Taking medication that affects macronutrient metabolism and/or the ability to participate in strenuous exercise
- Living in areas that are more than 1,200 m, or traveled to areas that are more than 1,200 m for five days or more within 2 months of data collection
- Evidence of apnea or other sleeping disorders
- Prior diagnosis of high altitude pulmonary edema or high altitude cerebral edema
- Presence of asthma or respiratory tract infections
- Smoking or vaping
- Taking medications that interfere with oxygen delivery and transport
- Anemia (HCT <38% and HBG <12.5 g/dL) and Sickle Cell Anemia/Trait
- Blood donation within 8 weeks of beginning the study
- Unwilling or unable to consume study diets or foods provided due to personal preference, dietary restrictions, and/or food allergies
- Unwilling or unable to adhere to study physical restrictions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pioglitazone
Pioglitazone administered as a 15 mg oral dose per day for 5 days
|
Pioglitazone (PIO) will be administered as a 15 mg oral dose per day for 5 days
Other Names:
|
|
Experimental: Placebo
Microcrystalline cellulose pill administered as an oral dose per day for 5 days
|
100% microcrystalline cellulos
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of Exogenous Glucose Oxidation
Time Frame: 8 hours
|
Determine the effects of PIO on exogenous glucose oxidation (g/min) during exercise under acute HA exposure compared to PLA
|
8 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Concentration of Interleukin-6
Time Frame: 8 hours
|
Determine the effects of PIO on inflammation during acute HA exposure compared to PLA.
|
8 hours
|
|
Concentration of Serum Hemoglobin
Time Frame: 8 hours
|
Determine the effects of PIO on markers of iron status during acute HA exposure compared to PLA
|
8 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 22-07H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.